Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M Munita; Samuel L Aitken; William R Miller; Federico Perez; Rossana Rosa; Luis A Shimose; Paola N Lichtenberger; Lilian M Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T Tran; Javier Adachi; Robert Rakita; Samuel Shelburne; Robert A Bonomo; Cesar A Arias

doi:10.1093/cid/cix014

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.

Authors

Jose M Munita^{1

2

3}, Samuel L Aitken^{1

4}, William R Miller^{1

2}, Federico Perez⁵, Rossana Rosa^{6

7}, Luis A Shimose^{6

7}, Paola N Lichtenberger⁷, Lilian M Abbo^{6

7}, Rupali Jain⁸, Masayuki Nigo², Audrey Wanger⁹, Rafael Araos³, Truc T Tran^{1

2}, Javier Adachi¹⁰, Robert Rakita¹¹, Samuel Shelburne¹⁰, Robert A Bonomo⁵, Cesar A Arias^{1

2

12}

Affiliations

¹ Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.
² Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.
³ Genomics and Resistant Microbes Group, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
⁴ Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
⁵ Cleveland Veterans Affairs Medical Center Case Western Reserve University, Ohio.
⁶ Department of Medicine, Jackson Memorial Hospital, FL.
⁷ Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida.
⁸ Department of Pharmacy, University of Texas McGovern Medical School, Houston.
⁹ Department of Pathology and Laboratory Medicine, University of Texas McGovern Medical School, Houston.
¹⁰ Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston.
¹¹ Division of Allergy and Infectious Diseases, University of Washington, Seattle.
¹² International Center for Antimicrobial Resistance, Universidad El Bosque, Bogota, Colombia.

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

Keywords: P. aeruginosa; carbapenem resistant; ceftolozane; multidrug resistant.

Publication types

Multicenter Study

MeSH terms

Adult
Aged
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / pharmacology*
Anti-Bacterial Agents / therapeutic use
Carbapenems / pharmacology*
Cephalosporins / adverse effects
Cephalosporins / therapeutic use*
Female
Humans
Male
Middle Aged
Penicillanic Acid / adverse effects
Penicillanic Acid / analogs & derivatives*
Penicillanic Acid / therapeutic use
Pseudomonas Infections / drug therapy*
Pseudomonas Infections / epidemiology
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Retrospective Studies
Tazobactam

Substances

Anti-Bacterial Agents
Carbapenems
Cephalosporins
ceftolozane
Penicillanic Acid
Tazobactam

Abstract

Publication types

MeSH terms

Substances

Grants and funding